• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过粪便钙卫蛋白评估艰难梭菌感染严重程度:一项初步研究。

Clostridoides difficile Infection Severity Assessment by Fecal Calprotectin: A Pilot Study.

作者信息

Voicu Mirela Nicoleta, Ahmet Ana Maria, Turcu-Stiolica Adina, Ungureanu Bogdan Silviu, Dragoescu Alice Nicoleta, Popescu Florica

机构信息

Phd Student, Department of Pharmacology, University of Medicine and Pharmacy of Craiova, Romania.

Student, University of Medicine and Pharmacy of Craiova, Romania.

出版信息

Curr Health Sci J. 2021 Apr-Jun;47(2):204-208. doi: 10.12865/CHSJ.47.02.09. Epub 2021 Jun 30.

DOI:10.12865/CHSJ.47.02.09
PMID:34765239
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8551903/
Abstract

UNLABELLED

infection (CDI) is the leading cause of antibiotic related diarrhea therapy and may associate high morbidity and mortality. Providing a potential biomarker to assess disease severity may help physicians in choosing the right treatment.

METHODS

This was a prospective, single-centre cohort study which included patients diagnosed with CDI which were assessed by fecal calprotectin (FC).

RESULTS

Patients included had a mean of 69.29 years of age, 54.23% of male gender. Patients diagnosed with mild CDI had a mean ATLAS score of 3.39 (±1.24), statistically lower (p<0.001) than patients with severe CDI who had a mean ATLAS score of 7.33 (±0.77). Fecal calprotectin concentrations were significantly higher (p<0.001) in the severe CDI patients (615.14μg/g; IQR, 403.62-784.4μg/g) than in the mild CDI patients (195.42μg/g; IQR, 131.12-298.59μg/g). We suggest a cut-off of 290.09μg/g for the predictive marker of fecal calprotectin, which permitted to identify patients with severe and mild CDI, having 100% sensitivity and 76% specificity.

CONCLUSIONS

Our findings point out the potential that FC might have, as a biomarker for disease severity. However, future multicentre studies and in larger cohort need to validate the results.

摘要

未标注

艰难梭菌感染(CDI)是抗生素相关性腹泻治疗的主要原因,可能伴有高发病率和死亡率。提供一种潜在的生物标志物来评估疾病严重程度可能有助于医生选择正确的治疗方法。

方法

这是一项前瞻性、单中心队列研究,纳入了经粪便钙卫蛋白(FC)评估诊断为CDI的患者。

结果

纳入患者的平均年龄为69.29岁,男性占54.23%。诊断为轻度CDI的患者平均ATLAS评分为3.39(±1.24),在统计学上低于重度CDI患者(平均ATLAS评分为7.33(±0.77),p<0.001)。重度CDI患者的粪便钙卫蛋白浓度(615.14μg/g;四分位间距,403.62 - 784.4μg/g)显著高于轻度CDI患者(195.42μg/g;四分位间距,131.12 - 298.59μg/g,p<0.001)。我们建议将粪便钙卫蛋白预测标志物的临界值设定为290.09μg/g,这能够识别重度和轻度CDI患者,灵敏度为100%,特异性为76%。

结论

我们的研究结果指出了FC作为疾病严重程度生物标志物的潜在可能性。然而,未来需要多中心研究以及更大规模的队列来验证这些结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c1b/8551903/9df732af44a8/CHSJ-47-02-204-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c1b/8551903/6157b112dfb9/CHSJ-47-02-204-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c1b/8551903/9df732af44a8/CHSJ-47-02-204-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c1b/8551903/6157b112dfb9/CHSJ-47-02-204-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c1b/8551903/9df732af44a8/CHSJ-47-02-204-fig2.jpg

相似文献

1
Clostridoides difficile Infection Severity Assessment by Fecal Calprotectin: A Pilot Study.通过粪便钙卫蛋白评估艰难梭菌感染严重程度:一项初步研究。
Curr Health Sci J. 2021 Apr-Jun;47(2):204-208. doi: 10.12865/CHSJ.47.02.09. Epub 2021 Jun 30.
2
Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with Clostridium difficile infection.艰难梭菌感染患者粪便钙卫蛋白水平、疾病严重程度与高毒力核糖体分型027菌株之间的相关性
BMC Infect Dis. 2016 Jun 22;16:309. doi: 10.1186/s12879-016-1618-8.
3
The level of fecal calprotectin significantly correlates with Clostridium difficile infection severity.粪便钙卫蛋白水平与艰难梭菌感染严重程度显著相关。
Folia Med Cracov. 2019;59(3):53-65. doi: 10.24425/fmc.2019.131136.
4
Fecal Calprotectin Level Reflects the Severity of Clostridium difficile Infection.粪便钙卫蛋白水平反映艰难梭菌感染的严重程度。
Ann Lab Med. 2017 Jan;37(1):53-57. doi: 10.3343/alm.2017.37.1.53.
5
Predictive value of fecal calprotectin and lactoferrin levels for negative outcomes in Clostridioides difficile infection.粪便钙卫蛋白和乳铁蛋白水平对艰难梭菌感染阴性结局的预测价值。
Eur J Clin Microbiol Infect Dis. 2024 Feb;43(2):313-324. doi: 10.1007/s10096-023-04729-z. Epub 2023 Dec 11.
6
The value of fecal calprotectin in infection: A systematic review.粪便钙卫蛋白在感染中的价值:一项系统综述。
Front Physiol. 2022 Aug 3;13:881816. doi: 10.3389/fphys.2022.881816. eCollection 2022.
7
Elevated fecal calprotectin associates with adverse outcomes from Clostridium difficile infection in older adults.粪便钙卫蛋白水平升高与老年人群艰难梭菌感染的不良结局相关。
Infect Dis (Lond). 2016 Sep;48(9):663-9. doi: 10.1080/23744235.2016.1186832. Epub 2016 May 20.
8
Fecal calprotectin in management of Clostridium difficile infection: a longitudinal study.粪便钙卫蛋白在艰难梭菌感染管理中的应用:一项纵向研究。
Scand J Gastroenterol. 2018 May;53(5):567-572. doi: 10.1080/00365521.2017.1392598. Epub 2017 Oct 24.
9
Quantitative Fecal Lactoferrin as a Biomarker for Severe Infection in Hospitalized Patients.定量粪便乳铁蛋白作为住院患者严重感染的生物标志物
J Geriatr Palliat Care. 2014;2(1):3. doi: 10.13188/2373-1133.1000006.
10
Systemic Inflammatory Mediators Are Effective Biomarkers for Predicting Adverse Outcomes in Clostridioides difficile Infection.系统炎症介质是预测艰难梭菌感染不良结局的有效生物标志物。
mBio. 2020 May 5;11(3):e00180-20. doi: 10.1128/mBio.00180-20.

引用本文的文献

1
infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options.感染:历史、流行病学、风险因素、预防、临床表现、治疗和未来选择。
Clin Microbiol Rev. 2024 Jun 13;37(2):e0013523. doi: 10.1128/cmr.00135-23. Epub 2024 Feb 29.
2
The value of fecal calprotectin in infection: A systematic review.粪便钙卫蛋白在感染中的价值:一项系统综述。
Front Physiol. 2022 Aug 3;13:881816. doi: 10.3389/fphys.2022.881816. eCollection 2022.

本文引用的文献

1
Usefulness of Fecal Calprotectin in the Management of Patients with Toxigenic .粪便钙卫蛋白在产毒素患者管理中的作用
J Clin Med. 2021 Apr 12;10(8):1627. doi: 10.3390/jcm10081627.
2
Clinical utility of fecal calprotectin: potential applications beyond inflammatory bowel disease for the primary care physician.粪便钙卫蛋白的临床应用:基层医疗医生在炎症性肠病之外的潜在应用
Ann Gastroenterol. 2019 Sep-Oct;32(5):425-430. doi: 10.20524/aog.2019.0394. Epub 2019 Jun 20.
3
Recurrent Infection: Risk Factors, Treatment, and Prevention.
反复感染:危险因素、治疗和预防。
Gut Liver. 2019 Jan 15;13(1):16-24. doi: 10.5009/gnl18071.
4
Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis.粪便钙卫蛋白在评估炎症性肠病内镜活动度中的应用:一项诊断准确性的荟萃分析
J Gastrointestin Liver Dis. 2018 Sep;27(3):299-306. doi: 10.15403/jgld.2014.1121.273.pti.
5
Update of treatment algorithms for Clostridium difficile infection.艰难梭菌感染治疗方案的更新。
Clin Microbiol Infect. 2018 May;24(5):452-462. doi: 10.1016/j.cmi.2017.12.022. Epub 2018 Jan 6.
6
Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with Clostridium difficile infection.艰难梭菌感染患者粪便钙卫蛋白水平、疾病严重程度与高毒力核糖体分型027菌株之间的相关性
BMC Infect Dis. 2016 Jun 22;16:309. doi: 10.1186/s12879-016-1618-8.
7
Clostridium difficile infection: epidemiology, diagnosis and understanding transmission.艰难梭菌感染:流行病学、诊断和传播途径的理解。
Nat Rev Gastroenterol Hepatol. 2016 Apr;13(4):206-16. doi: 10.1038/nrgastro.2016.25. Epub 2016 Mar 9.
8
Diagnosis and treatment of Clostridium difficile in adults: a systematic review.成人艰难梭菌的诊断与治疗:系统评价。
JAMA. 2015 Jan 27;313(4):398-408. doi: 10.1001/jama.2014.17103.
9
Clostridium difficile infection: a worldwide disease.艰难梭菌感染:一种全球性疾病。
Gut Liver. 2014 Jan;8(1):1-6. doi: 10.5009/gnl.2014.8.1.1. Epub 2014 Jan 13.
10
European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection.欧洲临床微生物学和传染病学会:艰难梭菌感染治疗指南文件的更新。
Clin Microbiol Infect. 2014 Mar;20 Suppl 2:1-26. doi: 10.1111/1469-0691.12418.